Rabbit Polyclonal GSDMC Antibody

GSDMC (Gasdermin C), a member of the gasdermin protein family, is primarily associated with inflammatory cell death (pyroptosis) and immune regulation. Unlike other gasdermins (e.g., GSDMD), GSDMC was initially linked to epithelial barrier integrity and differentiation. Recent studies highlight its role in cancer progression, particularly in tumors like breast cancer and melanoma, where its overexpression correlates with metastasis, drug resistance, and poor prognosis. GSDMC is cleaved by caspase-8 (not caspase-1/4/5/11 in canonical pyroptosis) under chemotherapy stress (e.g., doxorubicin), releasing its N-terminal pore-forming domain to trigger pyroptosis, bridging apoptosis and pyroptosis pathways. This cleavage-dependent activation suggests context-specific roles in inflammation and cancer. GSDMC antibodies are critical tools for detecting its expression, localization, and activation status in research. They enable studies on its dual roles in tumor suppression (via pyroptosis) and promotion (via metastasis pathways) and its potential as a therapeutic target. Commercial antibodies target specific epitopes (full-length, N-terminal, or cleaved forms) to support functional assays (Western blot, IHC, flow cytometry). However, antibody validation remains essential due to homology within the gasdermin family. Ongoing research explores GSDMC's interactions with immune checkpoints (e.g., PD-L1) and its utility in predicting therapeutic responses.